SI3583120T1 - Inženirani polipeptidi, ki vezujejo transferinske receptorje - Google Patents

Inženirani polipeptidi, ki vezujejo transferinske receptorje

Info

Publication number
SI3583120T1
SI3583120T1 SI201830823T SI201830823T SI3583120T1 SI 3583120 T1 SI3583120 T1 SI 3583120T1 SI 201830823 T SI201830823 T SI 201830823T SI 201830823 T SI201830823 T SI 201830823T SI 3583120 T1 SI3583120 T1 SI 3583120T1
Authority
SI
Slovenia
Prior art keywords
receptor binding
transferrin receptor
binding polypeptides
engineered transferrin
engineered
Prior art date
Application number
SI201830823T
Other languages
English (en)
Inventor
Xiaocheng Chen
Mark S. Dennis
Mihalis Kariolis
Adam P. Silverman
Ankita Srivastava
Ryan J. Watts
Robert C. Wells
Joy Yu Zuchero
Original Assignee
Denali Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc. filed Critical Denali Therapeutics Inc.
Publication of SI3583120T1 publication Critical patent/SI3583120T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
SI201830823T 2017-02-17 2018-02-15 Inženirani polipeptidi, ki vezujejo transferinske receptorje SI3583120T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762460692P 2017-02-17 2017-02-17
US201762543658P 2017-08-10 2017-08-10
US201762583314P 2017-11-08 2017-11-08
PCT/US2018/018371 WO2018152326A1 (en) 2017-02-17 2018-02-15 Engineered transferrin receptor binding polypeptides
EP18708025.4A EP3583120B1 (en) 2017-02-17 2018-02-15 Engineered transferrin receptor binding polypeptides

Publications (1)

Publication Number Publication Date
SI3583120T1 true SI3583120T1 (sl) 2023-02-28

Family

ID=61521837

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830823T SI3583120T1 (sl) 2017-02-17 2018-02-15 Inženirani polipeptidi, ki vezujejo transferinske receptorje

Country Status (32)

Country Link
US (4) US11795232B2 (sl)
EP (2) EP4169937A1 (sl)
JP (2) JP2020508049A (sl)
KR (1) KR20190129868A (sl)
CN (1) CN110506055A (sl)
AU (2) AU2018221731C1 (sl)
BR (1) BR112019016989A2 (sl)
CA (1) CA3053375A1 (sl)
CL (1) CL2019002307A1 (sl)
CO (1) CO2019008873A2 (sl)
CR (1) CR20190372A (sl)
DK (1) DK3583120T3 (sl)
EC (1) ECSP19058592A (sl)
ES (1) ES2932759T3 (sl)
FI (1) FI3583120T3 (sl)
HR (1) HRP20221505T1 (sl)
HU (1) HUE060983T2 (sl)
IL (2) IL268660B2 (sl)
LT (1) LT3583120T (sl)
MD (1) MD3583120T2 (sl)
MX (2) MX2019009818A (sl)
NZ (1) NZ756763A (sl)
PE (1) PE20191551A1 (sl)
PH (1) PH12019550147A1 (sl)
PL (1) PL3583120T3 (sl)
PT (1) PT3583120T (sl)
RS (1) RS63818B1 (sl)
SG (1) SG11201907427YA (sl)
SI (1) SI3583120T1 (sl)
TW (1) TWI797106B (sl)
UA (1) UA127985C2 (sl)
WO (1) WO2018152326A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
CN112839955A (zh) * 2018-08-16 2021-05-25 戴纳立制药公司 经工程改造双特异性蛋白
EA202190603A1 (ru) * 2018-08-22 2021-07-14 Денали Терапьютикс Инк. Полипептиды анти-her2 и способы их применения
WO2021133907A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants
EP4081536A1 (en) 2019-12-23 2022-11-02 Denali Therapeutics Inc. Progranulin variants
TW202128771A (zh) 2020-01-13 2021-08-01 美商戴納立製藥公司 抗trem2 抗體及其使用方法
AU2021208482A1 (en) * 2020-01-13 2022-07-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN111110834A (zh) * 2020-02-24 2020-05-08 中国科学院昆明动物研究所 转铁蛋白或过表达转铁蛋白在制备治疗和/或预防溃疡性结肠炎的药物中的应用
CA3197506A1 (en) 2020-10-14 2022-04-21 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
TW202315638A (zh) 2021-07-01 2023-04-16 美商得納利醫療公司 靶向運鐵蛋白受體之寡核酸苷偶聯物
WO2023114510A2 (en) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024026488A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
US20240052051A1 (en) 2022-07-29 2024-02-15 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024064753A1 (en) * 2022-09-20 2024-03-28 Dana-Farber Cancer Institute, Inc. Reversible control of chimeric antigen receptor t cells

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
FR2705194A1 (fr) 1993-05-21 1994-11-25 Transgene Sa Animal transgénique exprimant une transferrine d'origine humaine.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
WO2001016181A2 (en) 1999-08-30 2001-03-08 New York University School Of Medicine Crystal structures of domains of receptor protein tyrosine kinases and their ligands
JP2003525038A (ja) 2000-02-08 2003-08-26 ユニバーシティー オブ ブリティッシュ コロンビア 治療薬をスクリーニングするための組成物および方法
JP2001238681A (ja) 2000-03-03 2001-09-04 Japan Science & Technology Corp 共培養による血液脳関門再構築モデル
WO2002044329A2 (en) 2000-11-30 2002-06-06 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
JP2005501230A (ja) 2001-06-29 2005-01-13 ワイス 血液−脳関門透過の予測に有用な方法および組成物
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
ES2564688T3 (es) 2001-10-10 2016-03-28 Ratiopharm Gmbh Remodelación y glicoconjugación de poli(éter) a eritropoyetina
US20030074141A1 (en) 2001-10-15 2003-04-17 Camitro Corporation Meta-models for predicting blood brain barrier penetration based on simple physicochemical descriptors
EP1545595B1 (en) * 2002-08-30 2010-07-07 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7592143B2 (en) 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US20050170394A1 (en) 2004-01-30 2005-08-04 Xenoport, Inc. GLUT1 transporters expressed in blood brain barrier cells
GB0403490D0 (en) 2004-02-17 2004-03-24 Daniolabs Ltd Screening methods
FR2871162B1 (fr) 2004-06-02 2007-06-29 Univ Paris 7 Denis Diderot Materiau de surface modifiee, son procede de preparation et ses utilisations
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1817410B1 (en) 2004-11-29 2015-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human blood brain barrier model
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
US8900865B2 (en) 2005-12-14 2014-12-02 The Invention Science Fund I, Llc Blood brain barrier device
JP5113332B2 (ja) 2005-12-19 2013-01-09 正美 丹羽 血液脳関門インヴィトロ・モデル、病態血液脳関門インヴィトロ・モデル、及びこれを用いた薬物スクリーニング方法、病態血液脳関門機能解析方法、病因解析方法
US7744879B2 (en) 2006-06-07 2010-06-29 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20080044847A1 (en) 2006-06-23 2008-02-21 Shusta Eric V Blood-Brain Barrier Model
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
EP2167135A2 (en) 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
US8580927B2 (en) 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
WO2010014622A2 (en) 2008-07-28 2010-02-04 Fondazione Istituto Firc Di Oncologica Molecolare (Ifom) In vitro model for modulating the blood brain barrier and methods of screening
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US8417465B2 (en) 2009-11-04 2013-04-09 Cfd Research Corporation Synthetic microfluidic blood-brain barrier
WO2011100058A1 (en) 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
KR20130092589A (ko) 2010-10-29 2013-08-20 에프. 호프만-라 로슈 아게 Ｉｌ３３ ｎ―말단 도메인 결실을 갖는 염증의 쥣과 모델
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
LT2646470T (lt) 2010-11-30 2017-06-12 F. Hoffmann-La Roche Ag Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
EP2682401A4 (en) 2011-02-02 2015-06-03 Microbial Chem Res Found FOR OBTAINING THE BLOOD-BRAIN-DISABLED MEDICAMENT OUTPUT MATERIAL, PEPTIDE THEREOF AND USE THEREOF
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
WO2012143379A1 (en) 2011-04-20 2012-10-26 Roche Glycart Ag Method and constructs for the ph dependent passage of the blood-brain-barrier
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2839539C (en) 2011-06-30 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
EP2568051A1 (en) 2011-09-07 2013-03-13 Stallergenes S.A. Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
DK177327B1 (en) 2011-12-23 2013-01-14 Entomopharm Aps OPTIMIZED INSECT BASED EX VIVO MODEL FOR EXAMINATION OF BLOOD BRAIN BARRIER penetration and method of exposing the insect brain to chemical compounds
CN104204204A (zh) 2012-02-09 2014-12-10 中外制药株式会社 抗体的Fc区变异体
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
EP2825557B1 (en) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
EP2842969B1 (en) 2012-04-23 2018-03-14 NRL Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
CN104520325A (zh) 2012-05-21 2015-04-15 霍夫曼-拉罗奇有限公司 用于提高血脑屏障转运的安全性的方法
EP2855520B1 (en) 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
WO2013187495A1 (ja) 2012-06-14 2013-12-19 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
US9513280B2 (en) 2012-08-28 2016-12-06 University Of Utah Research Foundation Microfluidic biological barrier model and associated method
EP2890712B1 (en) 2012-08-29 2019-05-01 F.Hoffmann-La Roche Ag Blood brain barrier shuttle
US10590393B2 (en) 2012-11-08 2020-03-17 Wisconsin Alumni Research Foundation Retinoic acid enhanced human stem cell derived blood brain barrier model
US9932559B2 (en) 2012-11-16 2018-04-03 The Johns Hopkins University Platform for creating an artificial blood brain barrier
US20140212423A1 (en) 2012-12-04 2014-07-31 Abbvie, Inc. Blood-brain barrier penetrating dual specific binding proteins
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2971047A4 (en) 2013-03-15 2016-11-30 Alper Biotech Llc MONOCLONAL ANTIBODIES AGAINST TRANSFERRIN AND ANTIGENS OF THE TRANSFERRIN RECEPTOR, AND USES THEREOF
US20160040125A1 (en) 2013-03-26 2016-02-11 Biocant - Centro De Inovação Em Biotecnologia A human blood-brain barrier model derived from stem cells
TWI523945B (zh) 2013-03-29 2016-03-01 Nat Univ Chung Cheng Establishment of blood - brain barrier model in
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
US20140348754A1 (en) 2013-05-14 2014-11-27 California Institute Of Technology Method of Delivering Therapeutics and Imaging Agents to the Brain by Nanoparticles that Cross the Blood Brain Barrier
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
DK3004174T3 (da) 2013-05-31 2019-07-22 Zymeworks Inc Heteromultimerer med reduceret eller nedreguleret effektorfunktion
EA201600141A1 (ru) 2013-08-02 2016-09-30 Ф. Хоффманн-Ля Рош Аг Терапевтический слитый белок
ES2928155T3 (es) 2013-08-19 2022-11-15 S M Discovery Holdings Inc Composición de nanoadministración peptídica que se dirige a dos receptores
CA2922979A1 (en) 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN111499743B (zh) 2013-11-21 2024-01-12 豪夫迈·罗氏有限公司 抗-α-突触核蛋白抗体及使用方法
EP3450557A1 (en) 2013-12-25 2019-03-06 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
KR20160104628A (ko) 2014-01-03 2016-09-05 에프. 호프만-라 로슈 아게 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
EP3851452A1 (en) 2014-01-06 2021-07-21 F. Hoffmann-La Roche AG Monovalent blood brain barrier shuttle modules
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
RU2016136989A (ru) 2014-02-19 2018-03-22 Ф.Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
WO2015191934A2 (en) 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP2995949A1 (en) 2014-09-09 2016-03-16 Institut Pasteur New in vitro blood brain barrier model
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016079081A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
US11820975B2 (en) 2014-12-09 2023-11-21 National Research Council Of Canada Human blood brain barrier model
WO2016202343A1 (en) 2015-06-19 2016-12-22 Aalborg Universitet A triple co-culture model of the blood-brain barrier using primary porcine brain endothelial cells, porcine pericytes and porcine astrocytes
PL3313879T3 (pl) * 2015-06-24 2022-04-11 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny z dostosowanym powinowactwem
WO2016208696A1 (ja) 2015-06-24 2016-12-29 Ｊｃｒファーマ株式会社 Ｂｄｎｆを含む融合蛋白質
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
AU2016283343B2 (en) 2015-06-24 2022-05-19 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody permeating blood-brain barrier
EA038973B1 (ru) 2015-07-06 2021-11-17 Ридженерон Фармасьютикалз, Инк. Полиспецифические антигенсвязывающие молекулы и их применения
WO2017035119A1 (en) 2015-08-24 2017-03-02 National University Of Singapore Blood brain barrier model in a 3d co-culture microfluidic system
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
EP3411406A1 (en) 2016-02-05 2018-12-12 Genmab A/S Multispecific antigen-binding molecule with improved internalization characteristics
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
US20200317749A1 (en) 2016-07-01 2020-10-08 Denali Therapeutics Inc. Albumin variants for enhanced serum half-life
JP2019529345A (ja) 2016-07-14 2019-10-17 バイオアークティック アクティエボラーグ 脳送達タンパク質
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
TW201825123A (zh) 2016-12-19 2018-07-16 南韓商韓美藥品股份有限公司 用於腦部靶向的長效蛋白質共軛物
CN110100000B (zh) 2016-12-26 2023-06-20 Jcr制药股份有限公司 含有bdnf的融合蛋白
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
US11542321B2 (en) 2017-03-22 2023-01-03 Research Corporation Technologies, Inc. Engineered stable CH2 polypeptides
KR20200008148A (ko) 2017-05-18 2020-01-23 에프. 호프만-라 로슈 아게 치료용 항체의 적용-관련된 부반응의 감소
HUE063021T2 (hu) 2017-08-10 2023-12-28 Denali Therapeutics Inc Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek
CA3075285A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
EP3704149A1 (en) 2017-11-02 2020-09-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
MX2020007389A (es) 2018-01-10 2020-10-14 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina y usos de estos.
KR20190114907A (ko) 2018-03-30 2019-10-10 한미약품 주식회사 뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
AU2019288212A1 (en) 2018-06-18 2020-12-03 Denali Therapeutics Inc. Fusion proteins comprising progranulin
CN112839955A (zh) 2018-08-16 2021-05-25 戴纳立制药公司 经工程改造双特异性蛋白
EA202190603A1 (ru) 2018-08-22 2021-07-14 Денали Терапьютикс Инк. Полипептиды анти-her2 и способы их применения
US20210395381A1 (en) 2018-09-14 2021-12-23 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
JP2022513579A (ja) 2018-10-16 2022-02-09 デナリ セラピューティクス インコーポレイテッド プログラニュリン関連障害を処置及びモニタリングするための方法
EP3887401A2 (en) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
MA54450A (fr) 2018-12-10 2021-10-20 Denali Therapeutics Inc Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation
MX2021011612A (es) 2019-04-03 2021-12-10 Denali Therapeutics Inc Formulaciones de moleculas proteicas que comprenden iduronato 2-sulfatasa.
EP4081536A1 (en) 2019-12-23 2022-11-02 Denali Therapeutics Inc. Progranulin variants
AU2021208482A1 (en) 2020-01-13 2022-07-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
US20230092681A1 (en) 2020-02-07 2023-03-23 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
JP2023514371A (ja) 2020-02-19 2023-04-05 デナリ セラピューティクス インコーポレイテッド 操作された抗ｈｅｒ２二重特異性タンパク質
CA3197506A1 (en) 2020-10-14 2022-04-21 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

Also Published As

Publication number Publication date
AU2018221731A1 (en) 2019-09-19
PH12019550147A1 (en) 2020-06-15
IL268660A (en) 2019-10-31
IL268660B1 (en) 2023-11-01
DK3583120T3 (da) 2022-12-19
NZ756763A (en) 2023-04-28
US20240018253A1 (en) 2024-01-18
CR20190372A (es) 2019-10-17
RS63818B1 (sr) 2023-01-31
MX2023001964A (es) 2023-02-23
JP2020508049A (ja) 2020-03-19
UA127985C2 (uk) 2024-03-06
ECSP19058592A (es) 2019-08-30
SG11201907427YA (en) 2019-09-27
CO2019008873A2 (es) 2019-08-30
EP4169937A1 (en) 2023-04-26
AU2021240106A1 (en) 2021-10-28
AU2018221731C1 (en) 2021-11-18
CN110506055A (zh) 2019-11-26
PT3583120T (pt) 2022-12-15
LT3583120T (lt) 2022-12-27
ES2932759T3 (es) 2023-01-25
EP3583120A1 (en) 2019-12-25
US11795232B2 (en) 2023-10-24
US11912778B2 (en) 2024-02-27
CL2019002307A1 (es) 2020-01-17
EP3583120B1 (en) 2022-10-05
IL268660B2 (en) 2024-03-01
IL307373A (en) 2023-11-01
MX2019009818A (es) 2019-10-14
TW201843174A (zh) 2018-12-16
WO2018152326A1 (en) 2018-08-23
AU2018221731B2 (en) 2021-07-01
AU2021240106B2 (en) 2023-09-07
TWI797106B (zh) 2023-04-01
HUE060983T2 (hu) 2023-05-28
US20230235072A1 (en) 2023-07-27
US20200223935A1 (en) 2020-07-16
BR112019016989A2 (pt) 2020-05-26
PE20191551A1 (es) 2019-10-24
HRP20221505T1 (hr) 2023-02-17
PL3583120T3 (pl) 2023-01-09
CA3053375A1 (en) 2018-08-23
US20240141058A1 (en) 2024-05-02
JP2023100833A (ja) 2023-07-19
FI3583120T3 (fi) 2023-01-13
MD3583120T2 (ro) 2023-02-28
KR20190129868A (ko) 2019-11-20

Similar Documents

Publication Publication Date Title
IL268660A (en) Polypeptides that bind to a transgenic transferrin receptor
SI3665192T1 (sl) Inženiring polipeptidov, ki se vežejo na receptorje za transferine
HK1251480A1 (zh) Cd3結合多肽
IL272643A (en) Binders
ZA201906358B (en) Improved antigen binding receptors
IL274926A (en) Pyrazolopyrimidines with activity against respiratory syncytial virus
IL268288A (en) Binders
EP3625300C0 (en) ADHESIVES
IL270969A (en) Aggrecan-binding immunoglobulins
IL270949A (en) A protease and a polypeptide that binds to O-glycoproteins
IL268360B1 (en) Engineered concrete binding compound
IL269477A (en) Polypeptides that bind to IL-1R-1
GB201615588D0 (en) TSLP Binding Proteins
GB201702069D0 (en) Binding polypeptides
GB201801959D0 (en) Binding polypeptides
IL266419A (en) Binding peptides
GB201715149D0 (en) IL-ß binding antibody
GB201901704D0 (en) Binding polypeptides
GB201717958D0 (en) Novel polypeptides
GB201713296D0 (en) Binding agents
GB201713298D0 (en) Binding agents
GB201706915D0 (en) Novel polypeptides
GB201701351D0 (en) Binding agents
GB201618186D0 (en) Binding members
GB201403306D0 (en) Binding Polypeptides